Legislation is needed to clarify that whistleblowing should be viewed positively, like compliance, rather than negatively, like a form of corporate treachery that eventually unravels in costly, exhausting & embarrassing legal battles
-Georgina Halford-Hall
Whistleblowers need one place to go to find out where they stand, get support and advice, source the financial means to fight retaliation and get appropriate compensation for their damaged careers—for most #whistleblowers, whistleblowing is career ending
In response to what is referred to by some as the Reproducibility Crisis, the psychology community has been trialling various Open and Reproducible Science solutions. These initiatives are relatively new concepts to broader neuroscience @BritishNeuro #RRI bnacredibility.org.uk/academia
#AtoZofdementia
Once amyloid starts to affect brain cells, it is thought to trigger a cascade of events, much like starting a row of falling dominoes. The brain’s immune cells become overactive and start to cause more harm than good. Blood flow can also be affected. #AlzResearch
Your brain is the most complex thing in the universe. Billions of cells working together to control your emotions, memories, movement and speech. we can take steps to keep our brains healthy and reduce our risk of developing dementia later in life #scicomm
A CT scan involves combining a series of X-rays taken from different angles of the head to produce images of a person’s brain to rule out conditions that cause similar symptoms to dementia and show structure changes that occur in diseases like Alzheimer’s
Sanctions can be levied against institutions that fail to disclose details of such misconduct, do not investigate allegations in a timely and fair manner, or take inappropriate action. In extreme circumstances sanctions could include suspending funding from an entire organization
When an organisation submits a grant application to @wellcometrust, they must confirm that the lead applicant, has not had an allegation of harassment upheld against them for which there is either a current formal disciplinary warning or an active sanction wellcome.org/grant-funding/…
Ines Greco @Simon_Lovestone lab have successfully demonstrated how text mining and in silico analysis can help to derive valid biomarker candidates for Alzheimer’s disease. However, their analysis covers mining various data sources available until 2006 …nslational-medicine.biomedcentral.com/articles/10.11…
Using the combination of HypothesisFinder, the ADO, and the Gene/Protein detection system in SCAIView, Malhotra et al @ApitiusHofmann extracted 289 speculative biomarker statements for mild, 101 for moderate and 182 for severe stages of Alzheimer’s disease genomemedicine.biomedcentral.com/articles/10.11…
@ApitiusHofmann et al describe a panel of bioinformatics and modeling approaches that have been developed to identify candidate mechanisms of neurodegenerative diseases such as Alzheimer’s and Parkinson’s based on publicly available data and knowledge mdpi.com/1422-0067/16/1…
Most approved “priority” medicines are developed by biotech rather than large pharmaceutical firms, says a two-decade study from Nektarios Oraiopoulos @noraio1 at the University of Cambridge Judge Business School @CambridgeJBS and Don Drakeman @advent_ls jbs.cam.ac.uk/insight/2020/b…
'The Risk of De-Risking Innovation: Optimal R&D Strategies in Ambiguous Environments' presents the first large-scale empirical validation of the theoretical literature predicting the superiority of decentralized parallel searches in ambiguous environments journals.sagepub.com/doi/10.1177/00…
Biotech companies created 40% more US Food & Drug Administration @US_FDA-approved “priority” drugs than the entire pharmaceutical industry from 1998 through 2016 while spending less than half as much, says a study by @noraio1 and Don Drakeman @CambridgeJBS jbs.cam.ac.uk/insight/2020/b…
With increased longevity how do we tackle age-related disease?
How can we engage & empower patients in their healthcare journeys?
How do we increase access to breakthrough therapies for patients with rare diseases?
What's the future of AI in drug discovery lifescienceintegrates.com/agenda/pharma-…